Convexia

Convexia is an AI-powered platform for sourcing and evaluating drug assets, combining specialized AI agents with specialist human review. It addresses the time and complexity involved in finding overlooked therapeutics and assessing their scientific, market, operational, and commercial viability. The platform sources assets globally from academia, stealth biotech, early-stage pharma, and IP repositories, then evaluates them across discovery, scientific diligence, market insight, execution risk, and probability of success.

The platform includes an Asset Discovery Agent, a Scientific Evaluation Stack using over 50 models for binding, ADME/PK, toxicity, immunogenicity, and mechanistic fit, a Market Insight Agent, an Operational Risk Agent with digital twin simulations, and a Probability of Success Model benchmarked against historical analog deals. Specialist human review is integrated throughout, culminating in a live roundtable with domain experts. Convexia also offers ConvexiaBench, a showcase comparing its agents with legacy tools and frontier LLMs, and allows licensing of individual modules such as the sourcing engine, diligence stack, and BD agent.

Convexia is designed for pharma, biotech, and investment groups evaluating drug assets. It offers a free trial without a credit card, with paid tiers for asset sourcing, report generation, and a Pro subscription. Individual modules can be licensed separately through pilots.